Alpha Cognition Inc. (ACOG): Cost of Revenue

Annual figures by period end, from SEC filings.

$603.4K

Year ended 2025-12-31

Period ended	Cost of Revenue	Change YoY	Source filing
2025-12-31	$603.4K	n/a	2026-03-31, From 2025-01-01

Cost of Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

Company	Year ended	Cost of Revenue	Change YoY
Alpha Cognition Inc. (ACOG)	2025-12-31	$603.4K	n/a
Lineage Cell Therapeutics, Inc. (LCTX)	2024-12-31	$334.0K	-50.2%
Pelthos Therapeutics Inc. (PTHS)	2025-12-31	$3.99M	n/a
LENZ Therapeutics, Inc. (LENZ)	2025-12-31	$418.0K	n/a
Zeo ScientifiX, Inc. (ZEOX)	2025-10-31	$931.0K	+10.3%
Scilex Holding Co (SCLX)	2025-12-31	$10.60M	-36.5%
Dyadic International Inc (DYAI)	2025-12-31	$2.32M	+94.2%
X4 Pharmaceuticals, Inc (XFOR)	2025-12-31	$5.76M	+622.3%
Kymera Therapeutics, Inc. (KYMR)	2025-12-31	$39.21M	-16.7%

Compare ACOG, LCTX, PTHS, LENZ side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗